Investing in strategic partnerships driving growth in the US and MENA

Annual Report 2025
Case study

Our purpose in action

In 2025, we accelerated growth through targeted partnerships, leveraging the complementary strengths of Hikma and our partners to achieve faster regulatory approvals, expanded market access, and portfolio expansion.

Key highlights:

Bio-Thera Solutions: capturing US autoimmune market share FDA approval and launch of Starjemza^™ (ustekinumab-hmny biosimilar) opens access to the biologic autoimmune treatment market. This collaboration with Bio-Thera Solutions demonstrates our model’s efficiency: our partner developed the product while we provide US market access, generating returns from our commercial infrastructure with minimal capital outlay.

Novugen: strategic oncology addition for our US specialty portfolio

Acquiring Novugen’s FDA-approved trametinib ANDA adds an important oncology asset to our US specialty portfolio, strengthening our competitive position in high-value therapeutic areas. Celltrion: scaling MENA biosimilar access Our strengthened alliance with global biosimilar leader Celltrion leverages our regional infrastructure to rapidly expand biosimilar availability across MENA. This partnership enhances our existing distribution network and market relationships while meeting growing regional demand for affordable biologics – creating new growth from established assets.

Value creation

For Hikma: Portfolio growth, market expansion, and revenue generation with optimised capital deployment and shared risk.

For partners: Access to established markets and commercial infrastructure they could not efficiently build independently.

For healthcare systems: Affordable treatment options that improve budget sustainability while maintaining high quality.

For patients: Earlier access to critical and affordable medicines.

“These 2025 partnerships validate our collaborative growth model. By identifying partners whose capabilities complement our market access strengths in the US and MENA, we are driving sustainable, capital-efficient growth while ensuring access to affordable and high-quality medicines.”

Bassam Kanaan
Executive Vice President, Corporate Development and M&A